Author Archives: Paul Older

Perioperative Functional Assessment.

Waite, R; Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, UK.
Hargreaves, D

British journal of hospital medicine (London, England : 2005) [Br J Hosp Med (Lond)] 2025 Jul 25; Vol. 86 (7), pp. 1-4.
Date of Electronic Publication: 2025 Jul 04.

Perioperative functional assessment is used to inform perioperative risk estimation and to target interventions such as prehabilitation, particularly in higher-risk cohorts. There are a variety of measures used and practice is variable. UK national guidance recommends cardiopulmonary exercise testing (CPET) or alternative objective measures when reduced functional capacity is identified on screening.

Daily validation using a metabolic simulator after regular calibration increases the quality of cardiopulmonary exercise testing.

Xu F; Department of Functional Testing Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Beijing, China.
Sun XG; Liu F; Zhai WX; Song Y; Tai WQ; Wang JN; Zhang YF;Zhou QQ; Shi C; Xie B; Chen JH; Huang J; Zhang ZF; Xiang MJ; Ye SD; Li L;

Journal of thoracic disease [J Thorac Dis] 2025 Jun 30; Vol. 17 (6), pp. 3863-3872.
Date of Electronic Publication: 2025 Jun 26.

Background: Gas exchange measurements, such as oxygen uptake ( INLINEMATH ) and carbon dioxide output ( INLINEMATH ), of cardiopulmonary exercise testing (CPET), are the key and gold standard for human cardiopulmonary functional evaluation. However, in terms of quality control, they are unstable and inaccurate. We used a metabolic simulator (MS) to detect measurement errors and enhance quality control.
Methods: In the Fuwai CPET laboratory, we performed CPET after systems had: (I) passed all the steps of regular system calibrations for flow and the partial pressure of O 2 and CO 2 ; and (II) passed the MS validation of INLINEMATH and INLINEMATH at low, medium, and high metabolic rates (MRs) daily from 2014 to 2023 for eight different CPET carts/systems. The absolute percentage difference of the 1 st validation of both INLINEMATH and INLINEMATH was calculated as follows: |[(measured – ideal) / ideal] × 100%|. A difference of <10% was set as the 1 st validation pass standard to run the laboratory, while a difference of ≥10% was classified as a 1 st validation failure. The absolute percentage difference of the 1 st validation among the eight carts/systems was compared using the Kruskal-Wallis H test. The rate of the 1 st validation failure, the number of validation days, and the median absolute percentage difference of the 1 st validation among the different CPET carts/systems were clustered using the hierarchical clustering method.
Results: In total, we completed 1,810 validation days for the eight CPET carts/systems, and found a 10,860 absolute percentage difference of the 1 st validation of INLINEMATH and INLINEMATH . The number of validation days completed by each cart/system and the 1 st validation failure rates were as follows: 8 (87.50%), 10 (90.00%), 54 (48.15%), 349 (43.27%), 20 (45.00%), 759 (21.21%), 525 (29.52%), and 85 (22.35%), respectively. The overall absolute percentage difference of the 1 st validation of each cart/system was 7.32% (P 25 , P 75 : 3.67%, 13.82%), 9.12% (P 25 , P 75 : 3.33%, 30.4%), 6.82% (P 25 , P 75 : 4.31%, 9.06%), 5.40% (P 25 , P 75 : 2.60%, 8.26%), 4.90% (P 25 , P 75 : 2.21%, 9.68%), 4.32% (P 25 , P 75 : 2.17%, 6.78%), 5.62% (P 25 , P 75 : 2.96%, 8.19%), and 5.35% (P 25 , P 75 : 2.55%, 7.81%), respectively. The Kruskal-Wallis H test results revealed significant differences among the eight carts/systems (H=274.86, P<0.001), and the pairwise comparisons showed that cart/system F had the lowest absolute percentage difference of 4.32% (P 25 , P 75 : 2.17%, 6.78%). The hierarchical cluster classified carts/systems A and B as one cluster, carts/systems C, E, and H as another cluster, and carts/systems D, F, and G as yet another cluster.
Conclusions: Using an MS can decrease measurement errors and variability for CPET. It can also improve the quality control of CPET.

Clinical and prognostic role of tricuspid regurgitation in incident patients with pulmonary arterial hypertension.

Ghio S; Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.;
S. Ghio and M.M. Moschella contributed equally as joint first authors.
Moschella MM; Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.; authors.
Baccelli A; Department of Respiratory Medicine, Royal Brompton Hospital, Guy’s and St Thomas’ NHS Foundation Trust, London, UK.
Savonitto G; Maldera M; Haji G; Davies R; Howard L; DLo Giudice F;

Aim: The clinical and prognostic role of tricuspid regurgitation (TR) in patients with pulmonary arterial hypertension (PAH) is still underappreciated. The main objective of the present study was to assess the prognostic value of TR in incident PAH patients.
Methods: Consecutive incident PAH patients were enrolled from 2011 to 2021. Patients underwent right heart catheterisation (RHC), cardiopulmonary exercise test (CPET), echocardiography including the degree of TR, tricuspid annular plane systolic excursion (TAPSE), ratio of TAPSE to systolic pulmonary artery pressure (sPAP), right ventricular (RV) areas and right atrial area. The primary end-point of survival analysis was all-cause death.
Results: Compared with patients with mild TR or no TR, those with TR of moderate degree or more had a worse TAPSE and TAPSE/sPAP, similar RV areas at echocardiography, worse peak oxygen consumption at CPET, and higher right atrial pressure and pulmonary vascular resistance at RHC. TR of a moderate degree or more was the only echocardiographic parameter associated with poor survival on Cox regression analyses (hazard ratio 3.34, 95% CI 1.73-6.45; p<0.001). The assessment of TR severity was crucial to determine the prognosis of patients who would have been categorised as low risk based on normal values of TAPSE or TAPSE/sPAP values.
Conclusion: In treatment-naive PAH patients, TR is an important echocardiographic prognostic indicator. In particular, as an emerging concept, assessment of severity of TR is critical to stratify the prognosis of patients who would have been considered at low risk based on normal values of TAPSE or of TAPSE/sPAP.

Decision making and outcomes in colorectal cancer and frailty: the DeCaF study.

Kler A; University of Liverpool, UK.; Countess of Chester Hospital NHS Foundation Trust, UK.& other Trusts
Tay J; Slawinski C; Welch C; Moug S;Blackwell S; Arnott R; Mitchell P; Heywood N;

nnals of the Royal College of Surgeons of England [Ann R Coll Surg Engl] 2025 Jul 15.
Date of Electronic Publication: 2025 Jul 15.

Introduction: Surgical resection is the main treatment for non-metastatic colorectal cancer (CRC). However, 6% of patients do not undergo surgery owing to frailty, according to the National Bowel Cancer Audit (NBOCA). The impact of preoperative evaluation and decision making on outcomes in frail patients is underexplored. This study examines variation in decision making for frail, older patients and the availability/use of resources by colorectal multidisciplinary teams (MDTs) across United Kingdom (UK) hospitals.
Methods: A UK-wide questionnaire was distributed to colorectal MDTs via the NBOCA newsletter and social media (18 May to 30 June 2021). Part A assessed MDT structure and resource use; Part B explored MDT decisions for two simulated 75-year-old patients with colonic and rectal cancer.
Results: Twenty MDTs responded. Decisions were MDT-driven in 55% ( n = 11) and surgeon-driven in 45% ( n = 9). Clinical examination (85%) and performance status (90%) were most used. Resource utilisation during MDT meetings varied across sites; for example, echocardiogram results were available and considered in MDT decision making in only 15% of centres. Cardiopulmonary exercise testing was used in 75%, anaesthetic assessment in 80%, frailty scoring in 25%, and preoperative geriatric assessment in 5%. Management of right-sided cancer was more consistent; rectal cancer decisions were more variable.
Conclusions: Variation exists across MDTs in the availability and use of resources when managing frail CRC patients. There is less consensus for rectal than caecal cancer. These findings highlight the need for standardised MDT protocols to support equitable, patient-centred care in complex cases.

Nasal vs. oral BREATHing WIn Strategies in healthy individuals during cardiorespiratory Exercise testing (BreathWISE).

Mapelli M; Centro Cardiologico Monzino, IRCCS, Milan, Italy.;
Salvioni E; Mattavelli I; Grilli G; Zerboni G; Nava A; Capra N; Galotta A;Biroli M; Bellini G; Dall’Asta M;Pasini E; De Paola A; Torzolini L; Mani N; Turri S; Campodonico J; Agostoni P;

PloS one [PLoS One] 2025 Jul 16; Vol. 20 (7), pp. e0326661.
Date of Electronic Publication: 2025 Jul 16 (Print Publication: 2025).

Background: Nasal and oral exclusive breathing modes have benefits and drawbacks during submaximal exercise. It is less known whether these responses would extend to anaerobic work performed at high intensity. The purpose of this study is to find the most efficient mode of breathing during different phases of a maximal exercise at cardiopulmonary exercise test (CPET).
Methods: Healthy subjects were recruited to perform 4 maximal CPETs (standard conditions (STD), exclusively nasal breathing (eNAS), exclusively oral breathing (eOR), partial nasal breathing (pNAS) with just one blocked nostril) using the same ramp protocol on an electronically braked cycle ergometer. Before the exercise a standard spirometry was executed in the same order. Twelve healthy subjects (28.6 ± 5.2 y, 50% males) performed the 4 CPETs within one month. Variables were analysed at rest, at anaerobic threshold (AT), at intermediate exercise steps, and at peak.
Results: Compared to STD, eOR, and pNAS conditions, eNAS was associated with a significant lower peakVO2, peakVCO2, peak ventilation, respiratory rate, VE/VCO2 slope, respiratory exchange ratio, and workload (p < 0.05 for all). Moreover, peak inspiration and peak expiration time were augmented, while forced expiratory volume and vital capacity at rest were reduced. Only minor differences were detected at rest or AT. eNAS breathing Borg scale was higher in all phases of the exercise.
Conclusions: In young healthy subjects, an exclusively nasal respiration induces significant impairment on peak exercise capacity at CPET due to ventilatory limitation, with only minor effects on metabolic parameters at rest and in submaximal effort.

The Basel Practicum

Dear Colleagues,

Imagine three days in the heart of Europe—three days where the very architects of modern cardiopulmonary exercise testing (CPET) “open their labs” and share their insights with you.

We are delighted to invite you to the 27th European Practicum on Cardiopulmonary Exercise Testing, taking place from 3–5 September 2025 in Basel, Switzerland—the only edition of this event in 2025.

This year’s practicum features a world-class faculty including:

  • Prof. Dr. Piergiuseppe Agostoni (Italy) – expert in heart failure and non-invasive hemodynamic monitoring
  • Prof. Daniel Dumitrescu (Germany) – expert in CPET formatting and pulmonary vascular disease
  • Prof. Dr. William Stringer (USA) – CPET pioneer and international authority on gas exchange analysis
  • Prof. Dr. Martin Brutsche (Switzerland) – specialist in integrative pulmonary diagnostics
  • Prof. Dr. Alfred Hager, Dr. Tim Takken, Prof. Dr. Marshall Riley, Prof. Dr. Denny Levett, Prof. Daniel Dumitrescu, Prof. Joachim Meyer, and many more – covering the full spectrum from pediatric CPET to elite athlete testing, rare diseases, and artificial intelligence in diagnostics

Under the Swiss skyline, you will:
✔ Conduct live CPET sessions on cutting-edge metabolic/gas-exchange systems
Decode complex data in real time with top-tier experts by your side
✔ Participate in small-group rotations for immersive, hands-on learning
✔ Submit your research for the Young Investigator Competition
✔ Enjoy Swiss precision and hospitality, including a networking dinner close to the river Rhein

If you’ve ever wanted to …
• train shoulder-to-shoulder with world-leading CPET experts,
• get hands-on with the newest metabolic cart technologies, and
• build collaborations that could redefine your clinical or research path –
… now is the time.

🕓 Important: Seats are limited and registration closes on 15 August 2025.

👉 Secure your spot now: cpx2025-dsbg@unibas.ch

With kind regards

Prof. Dr. Arno Schmidt-Trucksäss (Switzerland) – course chair and host, University of Basel

Iron Status, Anemia, and Functional Capacity in Adults with Congenital Heart Disease.

Phinicarides R; University Hospital Düsseldorf, Medical Faculty, Division of Cardiology, Düsseldorf, Germany.
Reuter I ; Wolff G; Karathanos A;Heidari H; Masyuk M; Pillekamp F; Kelm M;, Zeus T;, Klein K;

Diagnostics (Basel). 2025 Jun 30;15(13):1672.

Background: Congenital heart disease (CHD) affects approximately 9 per 1000 live births worldwide, with increasing prevalence due to improved survival. Today, over 90% of individuals with CHD reach adulthood, resulting in a growing population of adults with congenital heart disease (ACHD). Despite its clinical relevance, iron deficiency (ID) and anemia have been insufficiently studied in this group.
Objectives: To evaluate the prevalence and clinical impact of iron deficiency and anemia in ACHD, particularly their relationship with exercise capacity. Methods: We retrospectively analyzed 310 ACHD patients at University Hospital Düsseldorf between January 2017 and January 2019. Iron status was assessed using serum ferritin, transferrin saturation (TSAT), and hemoglobin levels. Exercise capacity was measured by cardiopulmonary exercise testing (VO2 max). Prevalence and clinical associations were compared with those reported in heart failure populations, using ESC guideline criteria. Analyses were adjusted for age, sex, and defect complexity.
Results: Iron deficiency (ID) was present in 183 patients (59.0%). Anemia was observed in 13 patients (4.2%), with 6 (46.2%) classified as microcytic and 5 (38.5%) as normocytic. Reduced exercise capacity, defined as VO2 max <80% of predicted, was present in 51 patients (16.5%), occurring more frequently in those with complex CHD (31.3% vs. 11.3%, p < 0.001). ID was associated with a trend toward lower VO2 max (21.3 vs. 23.5 mL/min/kg, p = 0.068), while anemia correlated with significantly reduced performance (19.8 ± 4.1 vs. 22.9 ± 6.3 mL/min/kg, p = 0.041).
Conclusions: Iron deficiency is highly prevalent, and anemia-though less common-was consistently associated with reduced functional capacity in ACHD. These findings highlight the need for targeted screening and management strategies in this growing patient population.

Please participate in the DELPHI study; a request from Paul Older

Dear all

There is an international study being performed to establish which patients are best investigated via CPET preoperatively. It is called DELPHI and involves international experts in our field.

Please get involved by going to the following website: it will not cost you anything.

https://data.castoredc.com/open-survey/A86617CD-0EDF-45A6-8119-322EF24798DF/88E967AF-2521-4DA5-B996-3487338D7B94/30298114-E420-486D-BEA0-7741B85E1642

Don’t forget to enrol yourself or your colleagues for the basel Practicum in September. The following link will take you to the website and allow you to enroll:

www.cpxinternational.com/practicum/basel-2025/

My best regards

Paul Older